Intracardiac thrombus – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:32:37 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Intracardiac thrombus – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Rivaroxaban, Dabigatran Etexilate, and Fluindione for Patients with Intra-Cardiac Thrombus https://clinicaltrials.eu/trial/study-on-rivaroxaban-dabigatran-etexilate-and-fluindione-for-patients-with-intra-cardiac-thrombus/ Wed, 29 Apr 2026 14:29:25 +0000 https://clinicaltrials.eu/trial/study-on-rivaroxaban-dabigatran-etexilate-and-fluindione-for-patients-with-intra-cardiac-thrombus/ This clinical trial is focused on studying treatments for a condition known as intra-cardiac thrombus, which refers to blood clots that form inside the heart. The study will compare different types of medications used to treat this condition. The medications being tested include Rivaroxaban (also known by its code name BAY59-7939), Dabigatran Etexilate, Apixaban, Fluindione, Acenocoumarol, and Warfarin. These medications are all taken orally, meaning they are swallowed in pill form.

The purpose of the study is to evaluate the impact of these medications on the overall health of patients with intra-cardiac thrombus over a period of six months. Participants in the study will be randomly assigned to receive one of the medications or a placebo. The study will monitor the effects of the medications on the reduction of blood clots and any potential side effects, such as bleeding. The goal is to determine which medication provides the best balance of benefits and risks for patients.

Throughout the study, participants will undergo regular check-ups and imaging tests, such as echocardiography or cardiac MRI, to assess the presence and size of the blood clots. The study will last for up to six months, during which time the participants’ health and response to the treatment will be closely monitored. The findings from this study aim to improve the treatment options available for patients with intra-cardiac thrombus, ultimately enhancing their quality of life and health outcomes.

]]>